Evidence map›Paper›PMID 40553344›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

The Use of AI for Phenotype-Genotype Mapping.

Jyoti Sharma, Prabudh Goel

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jyoti SharmaDepartment of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.
Prabudh GoelDepartment of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mapping of genotypes to phenotypes is a cornerstone of genetics, critical for understanding disease mechanisms and advancing precision medicine. The advent of next-generation sequencing (NGS) technologies has enabled the generation of extensive genomic datasets, yet the complexity and scale of these data demand innovative analytical approaches. Artificial intelligence (AI) has emerged as a transformative tool, integrating genotype and phenotype data, uncovering intricate patterns, and driving advancements in diagnosis, therapy, and research.AI applications in phenotype-genotype mapping span various machine learning and deep learning techniques. Supervised learning methods, such as Support Vector Machines (SVMs), Random Forests, and Gradient Boosting, predict variant pathogenicity and classify genetic risks by leveraging curated datasets. Unsupervised approaches, including k-Means clustering and hierarchical clustering, uncover hidden patterns in data, enabling the identification of disease subtypes and novel associations. Dimensionality reduction techniques like Principal Component Analysis (PCA) and t-Distributed Stochastic Neighbor Embedding (t-SNE) simplify high-dimensional genomic data for analysis and visualization. Neural networks, including Convolutional and Recurrent Neural Networks (CNNs and RNNs), excel at extracting insights from complex datasets like gene expression profiles and genomic sequences. These methodologies have found applications in rare disease diagnosis, drug discovery, and risk assessment for complex diseases. AI tools integrate genetic and phenotypic data to prioritize pathogenic variants, significantly improving diagnostic yields for unresolved cases. Multi-omic data integration, incorporating genomics, transcriptomics, and proteomics, offers a holistic perspective on genotype-phenotype relationships. In drug discovery, AI identifies therapeutic targets and predicts drug efficacy, accelerating the development of precision treatments.Despite its potential, challenges persist. Data heterogeneity, limited interpretability of AI models, privacy concerns, and insufficient datasets for rare diseases impede broader implementation. To address these issues, AI frameworks incorporate data standardization, explainability techniques like SHAP and LIME, federated learning for secure collaborative research, and data augmentation methods such as transfer learning and GANs. Future directions include the integration of multi-omic data, advanced explainable AI for clinical adoption, and the expansion of federated learning to facilitate cross-institutional collaborations. By bridging the gap between genotype and phenotype, AI-driven methodologies are transforming clinical genomics and personalized medicine. This chapter explores the methodologies, applications, challenges, and future prospects of AI in phenotype-genotype mapping, highlighting its pivotal role in advancing genetic research and improving healthcare outcomes.

Indexed as

Artificial IntelligenceChromosome MappingGenetic Association StudiesComputational BiologyGenomicsGenotypeHigh-Throughput Nucleotide SequencingHumansNeural Networks, ComputerPhenotypeSupport Vector MachineArtificial intelligenceGenetic disordersGraph Neural NetworksHuman Phenotype OntologyNext-generation sequencingPolygenic Risk Scores

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.